Type 2 Diabetes Care Is Moving Beyond A1c

For years, type 2 diabetes care was often summarized by one laboratory value: A1c.

The 2026 joint consensus report from the American Diabetes Association and the European Association for the Study of Diabetes makes a broader priority explicit.

Glucose still matters. But the purpose of treatment is not merely to produce a better number. It is to reduce the risk of cardiovascular disease, heart failure, kidney disease, liver disease and other complications while supporting quality of life.

Published October 2, 2026, the report updates the organizations' 2022 consensus for nonpregnant adults with type 2 diabetes. It integrates newer evidence on medication choice, obesity, chronic kidney disease, cardiovascular risk, metabolic dysfunction-associated steatotic liver disease, sleep, mental health and physical behavior across the full day.

The practical shift is important: treatment selection is increasingly driven by the health outcome a person needs—not only by how far a medication lowers A1c.

What changed

The new framework gives earlier and more prominent roles to medicines with demonstrated cardiovascular and kidney benefits.

For people with established cardiovascular disease, chronic kidney disease or heart failure, the report supports considering an SGLT2 inhibitor, a GLP-1 receptor agonist, or both, based on the condition and evidence for the individual drug.

It also states that these therapies may be appropriate early in care, potentially from diagnosis, when organ protection is a priority.

That is different from a strictly stepwise model in which every patient begins with the same medicine and adds other options only after glucose control worsens.

The report does not discard metformin. It reframes the decision. Metformin remains effective, inexpensive and familiar, but it is no longer the sole gateway to treatments chosen for cardiovascular or kidney protection.

A1c remains useful—but it is not the whole outcome

A1c estimates average glucose exposure over roughly two to three months. It is strongly connected to the risk of many diabetes complications and remains central to monitoring.

Its limitation is not that it is unimportant. It is that two medicines can lower A1c similarly while having different effects on heart failure, kidney decline, body weight, hypoglycemia and tolerability.

Modern diabetes care therefore asks several questions at once:

• Is glucose in an individualized target range?
• Does the person have cardiovascular disease, heart failure or kidney disease?
• Is excess adiposity contributing to health risk?
• Is fatty liver disease present or likely?
• What is the risk of hypoglycemia?
• Which adverse effects, costs and treatment burdens matter most?
• Can the plan be maintained in daily life?

The target is not a perfect biomarker in isolation. It is better long-term health with an acceptable treatment burden.

Earlier organ-protective therapy

SGLT2 inhibitors and GLP-1 receptor agonists were initially developed and tested as glucose-lowering medicines. Large outcome trials later showed that selected drugs in these classes can reduce particular cardiovascular and kidney events in defined populations.

That evidence changed the order of treatment decisions.

The 2026 consensus emphasizes that a medicine may be selected for heart or kidney protection even when additional glucose lowering is not the only—or primary—reason to use it.

This is established clinical evidence, not a biohacking extrapolation. The benefits come from randomized outcome trials in people with diabetes and related disease risks.

The boundary matters too: a class label does not mean every drug has identical evidence, every person is a candidate, or every combination improves outcomes. Product-specific indications, contraindications, kidney function, adverse effects, cost and patient preference remain relevant.

Combination therapy may begin earlier for selected patients

The report says earlier use of both an SGLT2 inhibitor and a GLP-1 receptor agonist should be considered for people with cardiovascular disease, chronic kidney disease or heart failure when the expected benefits justify the added treatment.

This is not a recommendation for everyone with type 2 diabetes to take both classes.

Evidence is strongest for particular drugs, outcomes and populations. Combining therapies can increase cost, complexity and the chance of adverse effects. The report frames decisions around shared decision-making and individual clinical priorities.

For evidence-minded readers, the key distinction is between additive biological plausibility and proven clinical benefit. Two mechanisms may complement each other, but the most reliable claims still come from trials that measure patient-important outcomes.

Weight is treated as a therapeutic target

The report gives weight management a larger role because excess adiposity can drive insulin resistance, sleep apnea, fatty liver disease, mobility limitations and cardiovascular risk.

This does not mean that every person with type 2 diabetes should pursue maximum weight loss.

Goals should reflect health status, preferences, nutrition, function and the risks of losing lean tissue. For some people, moderate and sustainable loss may meaningfully improve glucose regulation and related conditions. For others—especially older or frail adults—preserving muscle, strength and nutritional adequacy may be equally important.

Medication-assisted weight loss should therefore be judged by more than the scale. Tolerability, function, cardiometabolic outcomes and durability matter.

The report expands what counts as diabetes care

The consensus gives more attention to conditions and behaviors that are easy to miss in a glucose-centered visit.

Liver health

Metabolic dysfunction-associated steatotic liver disease is common in type 2 diabetes. The report supports identifying people at risk and using structured pathways to assess advanced fibrosis, rather than assuming normal liver enzymes exclude important disease.

Sleep and 24-hour behavior

Physical activity is not limited to scheduled exercise. Sedentary time, daily movement and sleep all influence metabolic health. The report places these behaviors in one 24-hour framework.

Obstructive sleep apnea also deserves attention because it is common in type 2 diabetes and can affect sleep quality, blood pressure and daytime function. Screening is not the same as diagnosis; suspected apnea still requires an appropriate clinical evaluation.

Psychological health

Diabetes distress, anxiety and depression can directly affect self-management and quality of life. Psychological support is not an optional extra when these problems interfere with care.

Oral health

The report highlights periodontal health, an often-overlooked part of chronic-disease care. This does not mean dental treatment replaces diabetes management; it means the mouth should not be treated as separate from the rest of the patient.

What the consensus does not mean

The report is authoritative guidance, but it is not an individual prescription.

It does not mean:

• everyone should switch medication immediately
• A1c no longer matters
• every SGLT2 inhibitor or GLP-1 drug has identical outcome evidence
• more medication is always better
• lifestyle, sleep and mental health can replace indicated medical treatment
• weight loss automatically equals better health
• a consumer wearable can diagnose diabetes or safely direct treatment changes

Consensus recommendations synthesize evidence and expert judgment. They guide decisions; they do not remove the need to evaluate the individual patient.

Practical takeaways

For someone living with type 2 diabetes, the most useful conversation is broader than “What is my A1c?”

Questions worth discussing with a qualified clinician include:

1. Do I have cardiovascular disease, heart failure, kidney disease or significant risk that should influence medication choice?
2. Have my kidney function and urine albumin been assessed appropriately?
3. Should I be evaluated for fatty liver disease or advanced fibrosis?
4. Are weight, muscle preservation and nutrition being considered together?
5. Could sleep apnea, poor sleep, depression, anxiety or diabetes distress be affecting my health?
6. What are the expected benefits, risks, costs and monitoring needs of each treatment option?
7. Which outcomes should we track besides A1c?

These are prompts for shared decision-making, not instructions to add, stop or change a medicine.

Who should be especially cautious

Medication choices require closer individual review in people who are pregnant or planning pregnancy; older adults with frailty or fall risk; people with advanced kidney or liver disease; anyone with recurrent hypoglycemia; those with a history of severe dehydration, ketoacidosis, pancreatitis or significant gastrointestinal disease; and people unable to maintain adequate nutrition or hydration.

The relevant cautions differ by medication and medical history. A clinician should review current drugs, kidney function, symptoms, access and monitoring needs before treatment changes.

The Modern Bio Take

The most important message in the 2026 ADA/EASD consensus is not that one drug class has won.

It is that type 2 diabetes care is being organized around outcomes that matter beyond a glucose number.

That means protecting the heart and kidneys when evidence supports it, addressing weight without ignoring muscle and nutrition, looking for liver disease and sleep apnea, and treating psychological and oral health as part of whole-person care.

For evidence-minded patients, the practical upgrade is simple: use A1c as one instrument on the dashboard—not as the entire dashboard.

Educational note: This article is for general educational purposes and is not medical advice. Diabetes diagnosis, monitoring and treatment changes require individualized review by a qualified healthcare professional. Do not start, stop or change prescription medication based on this article.

Primary sources

• American Diabetes Association and European Association for the Study of Diabetes. Management of Type 2 Diabetes, 2026: A Consensus Report. Published October 2, 2026.

• PubMed record: PMID 42825450.

• American Diabetes Association. Leading Diabetes Organizations Publish Joint Consensus Report on the Management of Type 2 Diabetes. October 2, 2026.